Most AI money in biotech chases drug discovery. Proximal Ventures is betting on everything that happens afterwards.
The early-stage firm, founded by Sahir Raoof, has closed its debut fund at $27.5 million. It plans to write pre-seed and seed checks into AI-native companies across the life-sciences value chain, with a deliberate focus on clinical development, manufacturing and commercialization -- the operational machinery that turns a promising molecule into a medicine.
The thesis rests on a gap. Venture investors have poured billions into AI drug-discovery platforms, but the slower, costlier steps after a candidate is found -- running trials, scaling production, navigating regulation and reaching patients -- remain largely un-automated. Proximal is betting that AI can attack the tools, infrastructure and services supporting that work, and capture a slice of the billions companies outsource to contract research and manufacturing organizations.
The fund has already backed seven startups, according to the firm. Raoof's pitch, as reported by TechCrunch, is that AI can transform the tools and services that support drug development -- not just the science of finding new compounds.
It is a modest fund by the standards of AI-biotech, where platform companies have raised far larger sums, and a $27.5 million vehicle is unlikely to move the industry on its own. But it reflects a maturing view of where the leverage lies: as discovery platforms proliferate, the bottleneck is increasingly downstream, in the trials and factories that stand between a good molecule and a shipped drug.




